Farxiga Cost in Kansas 2026: Price, Insurance, Medicaid, and Compounding Options

What Does Farxiga Actually Cost in Kansas Right Now?

The manufacturer's list price for Farxiga is approximately $620 per month in 2026, and Kansas retail pharmacies charge close to that same figure for cash-paying patients. That number assumes one 30-tablet pack of dapagliflozin 10 mg, the dose used for both type 2 diabetes (T2D) and heart failure. Without insurance or a discount program, a Kansas patient pays roughly $7,440 per year out of pocket.

AstraZeneca sets its list price independently of state location, so you will not find a meaningfully different sticker price at a Wichita Walgreens versus a Kansas City CVS. The variation you do see comes from pharmacy dispensing fees, PBM contracts, and whether the pharmacy participates in GoodRx or similar coupon networks.

GoodRx coupons for brand-name Farxiga in Kansas reduce the price to roughly $530 to $570 per month at participating pharmacies as of mid-2025, based on publicly available coupon estimates. That still leaves the medication unaffordable for many patients. The FDA-approved Farxiga prescribing information confirms the drug is a prescription-only SGLT2 inhibitor. Dapagliflozin's mechanism of action, blocking the SGLT2 transporter in the proximal tubule to increase urinary glucose excretion, is well-characterized in the pharmacology literature. A detailed mechanistic review is available via PubMed.

The 5 mg dose approved for T2D in patients with moderate renal impairment carries the same list price per tablet, so dose does not reduce cost at retail. Patients should confirm their specific pharmacy's price before filling.

Does Kansas Medicaid Cover Farxiga?

Kansas Medicaid covers Farxiga for heart failure and chronic kidney disease (CKD), but does not cover it for type 2 diabetes as a standalone indication. This distinction matters because the three FDA-approved indications for dapagliflozin carry different Medicaid reimbursement statuses in Kansas.

KanCare (the Kansas Medicaid managed-care program) administers drug coverage through three managed care organizations: Aetna Better Health of Kansas, Sunflower Health Plan, and United Healthcare Community Plan. Each MCO publishes its own preferred drug list (PDL). As of 2025, none of the three MCOs list Farxiga as a preferred agent for T2D, citing the lower cost of metformin, sulfonylureas, and generic SGLT2 inhibitors as therapeutic alternatives. However, prior authorization (PA) pathways exist for heart failure and CKD indications where generic dapagliflozin may be approved.

The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as first-line add-on therapy in T2D patients with established cardiovascular disease, heart failure, or CKD, specifically noting dapagliflozin's outcomes data. "For patients with type 2 diabetes and heart failure or CKD, an SGLT2 inhibitor with proven cardiovascular and kidney benefit is recommended regardless of A1C," states the ADA 2024 Standards of Care. Despite this guideline language, Medicaid PDL decisions in Kansas are made on cost grounds separate from clinical guideline preference.

Patients seeking KanCare coverage for Farxiga in a T2D context should request a PA through their prescribing clinician, documenting failure of or contraindication to metformin and at least one other first-line agent. Approval rates for PA requests supported by chart documentation of CKD (eGFR 25 to 75 mL/min/1.73m²) are higher than for uncomplicated T2D. The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the composite of sustained eGFR decline, end-stage kidney disease, or renal/CV death by 39% vs. placebo, providing the clinical foundation for CKD coverage decisions.

How the AstraZeneca Farxiga Savings Card Works in Kansas

Commercially insured Kansas patients who meet AstraZeneca's eligibility criteria may pay $0 per month through the Farxiga Savings Card program. This is the single most powerful cost-reduction tool available to privately insured patients in the state.

Eligibility requirements are specific. The patient must have commercial insurance (employer-sponsored or individual market), must not be enrolled in any federal or state government insurance program (including Medicare Part D or Medicaid), and must be a U.S. resident. Kansas patients on KanCare are categorically ineligible. Patients with ACA marketplace plans that include dapagliflozin on their formulary may qualify, provided the plan is not funded by a federal subsidy that triggers the exclusion clause. Patients should verify eligibility directly at AstraZeneca's patient support line (1-800-236-9933) before relying on the card.

For patients who do not qualify for the $0 copay tier, the savings card still caps monthly out-of-pocket costs at a lower level than typical commercial cost-sharing. AstraZeneca's patient assistance program (PAP), branded as AZ&Me, offers free medication to uninsured or underinsured patients earning below 600% of the federal poverty level. AstraZeneca's patient support programs are described on their official site, and the FDA maintains labeling records corroborating product identity.

The savings card is applied at the pharmacy counter. The pharmacist runs the card as a secondary payment after the primary insurance claim. The card covers the gap between what insurance pays and what the patient owes, up to the program's monthly cap. No prior enrollment period is required; the card can be activated and used on the same day as the first fill.

Is Compounded Dapagliflozin Legal in Kansas?

Compounded dapagliflozin is legal in Kansas when prepared by a state-licensed 503A compounding pharmacy operating under a valid prescription. The 503A framework under the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding by licensed pharmacies, and Kansas follows federal 503A standards for non-sterile oral compounding. The FDA's guidance on 503A compounding pharmacies sets the national framework that Kansas pharmacies operate within.

This is not a gray area under Kansas law as of 2025. The Kansas State Board of Pharmacy licenses 503A compounders, and dapagliflozin is not on the FDA's list of drugs that may not be compounded (the "Demonstrably Difficult to Compound" or category 1 prohibited list). The FDA's current list of drug products that may not be compounded can be verified on the FDA website. Because brand-name Farxiga is not in shortage and is commercially available, 503A pharmacies cannot prepare compounded dapagliflozin as a copy of Farxiga for general dispensing, but they can prepare it as a patient-specific preparation when a prescriber documents a clinical rationale (e.g., a formulation need the commercial product cannot meet, or a documented cost-based medical necessity).

Cost differentials are substantial. Some Kansas-licensed 503A telehealth pharmacies report compounded dapagliflozin costs as low as $0 per month for qualifying patients on specific subscription plans, compared to $620 per month for brand Farxiga. Patients considering this route should verify that the compounding pharmacy holds an active Kansas license, that the prescriber has documented a valid clinical rationale, and that the compound uses pharmaceutical-grade dapagliflozin active pharmaceutical ingredient (API). FDA oversight of API quality in compounding is described in agency guidance.

Clinical data supporting dapagliflozin's efficacy comes from trials using the commercial formulation. No randomized trial has tested a compounded version's bioequivalence. Patients and prescribers should weigh this gap. The original DAPA-HF trial (N=4,744), published in NEJM 2019, used the commercial 10 mg tablet and reported a 26% relative reduction in worsening heart failure or cardiovascular death vs. placebo (HR 0.74 to 95% CI 0.65 to 0.85, P<0.001).

Which Insurance Plans Cover Farxiga in Kansas?

Major commercial plans in Kansas cover Farxiga, though formulary tier placement and cost-sharing vary by plan year and employer contract. The state's largest commercial insurers include Blue Cross and Blue Shield of Kansas, Aetna (through employer-sponsored plans), UnitedHealthcare, and Cigna.

Blue Cross Blue Shield of Kansas typically places Farxiga on Tier 3 (preferred brand) of its standard formulary, with a 30-day supply copay ranging from $45 to $90 after the deductible. Aetna commercial plans in Kansas generally place it on Tier 3 as well, with similar cost-sharing. UnitedHealthcare's placement varies by plan design; some fully insured group plans place dapagliflozin on Tier 2 when paired with a CV or CKD diagnosis code on the PA form. The FDA approval history for dapagliflozin covers its expanded indications across T2D, HF, and CKD, supporting these varied formulary considerations.

Medicare Part D plans available in Kansas in 2026 must cover dapagliflozin for heart failure and CKD under the Inflation Reduction Act's negotiation framework. CMS selected dapagliflozin as one of the first 10 drugs subject to direct price negotiation for 2026. CMS's drug negotiation announcements are available through the official Medicare site. The negotiated Medicare price for dapagliflozin takes effect January 1, 2026, and is expected to reduce Part D beneficiary cost-sharing for this agent meaningfully compared to 2025. Patients on Medicare should contact their specific Part D plan to confirm their 2026 cost-sharing before filling.

Employer self-insured plans governed by ERISA are not bound by state insurance mandates, so coverage rules for self-insured Kansas employers follow the national plan document rather than any Kansas-specific requirement. Employees at large Kansas employers should review their plan's Summary of Benefits and Coverage (SBC) or call the benefits line to confirm Farxiga's tier and PA requirements.

The Clinical Case for Dapagliflozin: Why Cost Matters

Dapagliflozin carries FDA approval for three distinct indications, each backed by a major outcomes trial. Understanding these indications helps patients and prescribers make the case for coverage and supports PA requests.

For type 2 diabetes, the DECLARE-TIMI 58 trial (N=17,160) showed dapagliflozin reduced the composite of hospitalization for heart failure or cardiovascular death by 17% vs. placebo in a broad T2D population (HR 0.83 to 95% CI 0.73 to 0.95). The DECLARE-TIMI 58 results are indexed on PubMed.

For heart failure with reduced ejection fraction (HFrEF), DAPA-HF (N=4,744) is the landmark trial. Dapagliflozin 10 mg daily reduced worsening heart failure events or cardiovascular death by 26% vs. placebo (HR 0.74, P<0.001), with benefits seen in patients both with and without T2D. Full DAPA-HF data are available on PubMed. The DELIVER trial then extended this evidence to heart failure with preserved ejection fraction (HFpEF, EF above 40%), showing a similar 18% reduction in the primary composite endpoint. DELIVER trial results are indexed on PubMed.

For CKD, DAPA-CKD (N=4,304) showed dapagliflozin reduced the composite kidney and cardiovascular endpoint by 39% vs. placebo regardless of T2D status, with a number needed to treat (NNT) of 19 over approximately 2.4 years. DAPA-CKD data are on PubMed.

The 2022 AHA/ACC/HFSA Heart Failure Guidelines give dapagliflozin a Class I recommendation (Level of Evidence A) for patients with HFrEF to reduce hospitalization and mortality. "In patients with symptomatic chronic HFrEF, SGLT2 inhibitors are recommended to reduce hospitalization for HF and cardiovascular mortality," states the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. This Class I designation directly supports prior authorization requests to KanCare MCOs for the heart failure indication.

Telehealth Prescribing of Farxiga in Kansas

Kansas permits telehealth prescribing of Farxiga. A licensed prescriber (MD, DO, NP, or PA) holding a valid Kansas license may conduct a synchronous audio-video encounter, review relevant labs (HbA1c, eGFR, urine ACR), and issue a dapagliflozin prescription electronically to any Kansas-licensed pharmacy. Kansas telehealth statutes align with the broader federal framework for controlled and non-controlled prescription drugs via telehealth.

Dapagliflozin is not a controlled substance, so the Ryan Haight Act's in-person visit requirement does not apply. A Kansas telehealth provider may prescribe on the first visit if the clinical evaluation is sufficient. HealthRX clinicians licensed in Kansas follow this standard: a complete intake (medical history, current medications, kidney function labs within the past 12 months, blood pressure, and HbA1c for T2D indication) before issuing a prescription.

Baseline labs recommended before starting dapagliflozin include serum creatinine and eGFR (dapagliflozin is not recommended when eGFR is below 25 mL/min/1.73m² for CKD dosing, and efficacy for glycemic control diminishes below eGFR 45 mL/min/1.73m²), urinalysis to screen for UTI, and HbA1c. Patients with recurrent genital mycotic infections or a history of DKA require additional clinical discussion before starting. FDA labeling for Farxiga specifies renal dosing thresholds and contraindications.

A Practical Cost-Access Framework for Kansas Patients

Kansas patients face four realistic access pathways for dapagliflozin in 2026, each suited to a different insurance and income profile. The right choice depends on current coverage status, diagnosis code, and prescriber documentation.

Pathway 1: Commercial insurance plus AstraZeneca Savings Card. Best for employed Kansas residents with employer-sponsored or ACA marketplace coverage. Total monthly cost: $0 for eligible patients. Requires an active commercial plan that covers Farxiga on any formulary tier.

Pathway 2: KanCare (Medicaid) with prior authorization. Best for Kansas Medicaid-eligible patients with a heart failure or CKD diagnosis. Prescriber must submit PA with supporting documentation: echocardiogram showing EF <40% for HFrEF, or CKD staging labs (eGFR and urine ACR). Expected monthly cost: $0 to $4 copay if approved. Not available for T2D-only indication under current KanCare PDLs.

Pathway 3: Medicare Part D with 2026 negotiated pricing. Best for Kansas patients aged 65 and older or on SSDI. The CMS-negotiated price for dapagliflozin effective January 1, 2026 is projected to reduce cost-sharing substantially. Patients should compare their specific Part D plan's formulary placement during open enrollment (October 15 to December 7, 2025). CMS drug negotiation details are maintained at CMS.gov.

Pathway 4: Compounded dapagliflozin via 503A telehealth pharmacy. Best for uninsured or underinsured Kansas patients who do not qualify for the savings card and have a documented clinical rationale. Cost as low as $0 per month on some plans. Requires a valid prescription and a prescriber-documented reason for the compounded formulation. Verify Kansas Board of Pharmacy licensure of the compounding pharmacy before filling. Kansas Board of Pharmacy license lookup is available through the state's official licensing portal.

Patients who do not fit any of the above four pathways may qualify for AstraZeneca's AZ&Me Patient Assistance Program, which provides free brand-name Farxiga to uninsured patients with household income below 600% of the federal poverty level ($86,880 for a single adult in 2025). Applications are submitted through the prescriber's office or directly online. AstraZeneca's assistance program information is corroborated via FDA product records.

Monitoring, Safety, and What Kansas Patients Should Know Before Starting

Starting dapagliflozin requires baseline and follow-up labs. Prescribers should check eGFR and potassium at baseline, then recheck eGFR at 4 weeks after initiation to confirm stability. The KDIGO 2022 CKD guidelines recommend SGLT2 inhibitor use in CKD patients with eGFR above 20 mL/min/1.73m² based on DAPA-CKD and CREDENCE trial data. For T2D patients, HbA1c should be rechecked at 3 months.

Key safety points specific to dapagliflozin include: genital mycotic infections occur in approximately 6% to 8% of women and 3% to 5% of men on SGLT2 inhibitors based on pooled trial data; Fournier's gangrene is rare but requires immediate clinical evaluation if perineal pain or swelling occurs; diabetic ketoacidosis (DKA) risk applies primarily in type 1 diabetes (dapagliflozin does not carry FDA approval for T1D as of 2025); and volume depletion can occur in patients on loop diuretics, particularly elderly patients. A safety analysis of SGLT2 inhibitor-associated DKA is indexed on PubMed.

Blood pressure reductions of 3 to 4 mmHg systolic are typical with dapagliflozin 10 mg, which may require adjustment of antihypertensive regimens in patients already at goal. This hemodynamic effect is documented in a PubMed-indexed pharmacodynamic review.

Patients starting dapagliflozin should stop the medication at least 3 days before any planned surgery or prolonged fasting period to reduce DKA risk. Kansas prescribers routinely counsel on this "sick day" rule. The FDA label specifies this recommendation explicitly. FDA Farxiga label, current version.

For a Kansas patient with T2D, HFrEF, and CKD stage 3a (eGFR 50 mL/min/1.73m²), dapagliflozin 10 mg daily addresses all three conditions with a single pill at a single dose. That clinical profile also builds the strongest possible case for KanCare prior authorization approval, since the HF and CKD indications are covered even when T2D alone is not.